Mitophagy acts as a core barrier to effective immunotherapy in melanoma and other skin cancers
Mitophagy acts as a barrier to skin cancer immunotherapy
This narrative review explores how mitophagy functions as a barrier to immunotherapy in melanoma, cutaneous squamous cell carcinoma, and bas…
A cellular process called mitophagy may help skin cancers hide from the immune system, making it harder for certain treatments to work.
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
Sirolimus lowers skin cancer risk in kidney transplant patients
This meta-analysis of four randomized trials in kidney transplant recipients with prior cutaneous squamous cell carcinoma found that switchi…
A review of studies shows switching to sirolimus can cut skin cancer rates, but it may cause more side effects.